


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 7th day of August, 2005.

By



(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Matthew F. Brown, *et al.*

Serial No.: 10/687,380

Group Art Unit: 1621

Filed: October 16, 2003

Examiner: Chukwuma O. Nwaonicha

Title: HETEROARYL-HEXANOIC ACID
AMIDE DERIVATIVES
AS IMMUNOMODULATORY AGENTS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Sir:


Applicants hereby submit to the U.S. Patent and Trademark Office form PTO-FB-A820 to ensure compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56. The currently cited documents have not been previously submitted to the U.S. Patent and Trademark Office. This submission is intended to augment, and not replace, the Information Disclosure Statements filed previously February 2, 2004 and February 20, 2004.

In the judgment of the undersigned, portions of the documents cited in form PTO-FB-A820 may be material to the present application, however, the filing of this Information Disclosure Statement shall not be construed to be an admission that the documents cited are, or are considered to be, material with regard to patentability as defined in 37 C.F.R. § 1.56(b). The documents have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the documents. This statement is not a representation that the listed documents have an effective date early enough to be "prior art" within the meaning of 35 U.S.C. § 102 or § 103.

Because this Information Disclosure Statement is being filed after the mailing of a first Office Action on the merits, and before the mailing date of any final action under 37 C.F.R. § 1.113, the Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 pursuant to 37 C.F.R. § 1.97(c) and § 1.17(p). The Commissioner is further authorized to charge any additional fees or credit any overpayment to Account No. 16-1445.


Respectfully submitted,

Date: August 4, 2005



Christopher J. Verni
Attorney for Applicants
Reg. No. 48,322

Customer No. 28523
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-2032



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC25047A				SERIAL NO. 10/687,380							
									APPLICANT Matthew F. Brown, et al.											
									FILING DATE October 16, 2003				GROUP 1621							
U.S. PATENT DOCUMENTS																				
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE							
	US	3	1	1	9	7	4	2	1-28-64	Heimlich, et al.	167	82								
	US	3	4	9	2	3	9	7	1-27-70	Peters, et al.	424	20								
	US	3	5	3	8	2	1	4	11-3-70	Polli, et al.	424	19								
	US	4	0	6	0	5	9	8	11-29-77	Groppenbacher, et al.	424	33								
	US	4	1	7	3	6	2	6	11-6-79	Dempski, et al.	424	19								
	US	5	7	3	1	3	5	2	3-24-98	Lesieur, et al.	514	630								
	US	6	6	5	3	3	1	2	11-25-03	Auvin, et al.	514	252.19								
	US	6	6	9	6	4	9	4	2-24-04	Or, et al.	514	616								
FOREIGN PATENT DOCUMENTS																				
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION							
													YES	NO						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																				
			Lack, R.E., et al., J. Am Chem Soc., "Nuclear Magnetic Resonance Spectroscopy. Conformational Equilibria and Equilibration of 4,4-Difluorocyclohexanone and 6,6-Difluoro-cis-decal-2-ones", Vol. 90, pages 7001-7007 (1968)																	
EXAMINER DATE CONSIDERED																				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																				